Home 
Bratislava Medical Journal 2019 Bratislava Medical Journal Vol.120, No.4, p.295–298, 2019
Bratislava Medical Journal 2019 Bratislava Medical Journal Vol.120, No.4, p.295–298, 2019
Journal info
|
||||
Select Journal
Journals
Bratislava Medical Journal 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 Endocrine Regulations General Physiology and Biophysics Neoplasma Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Bratislava Medical Journal Vol.120, No.4, p.295–298, 2019 |
||
| Title: Nesfatin-1 and caspase-cleaved cytokeratin-18: Promising biomarkers for Alzheimer’s disease? | ||
| Author: M. Alpua, U. Kisa | ||
| Abstract: OBJECTIVES: To investigate the use of nesfatin-1 and caspase-cleaved cytokeratin-18 serum levels as biomarkers in Alzheimer’s disease. METHODS: The study group consisted of 39 patients with Alzheimer’s disease (AD) and 39 controls. Demographic characteristics including gender, age, body mass index, mini-mental status examination (MMSE) and duration of disease were recorded. The ELISA method was used to measure serum nesfatin-1 and CCCK-18 levels in serum samples. RESULTS: Serum nesfatin-1 levels were statistically significantly higher in the AD patient group than in controls. There was no significant difference between the groups with regards to serum CCCK-18 levels. Pearson analysis showed no significant correlation between serum nesfatin-1, serum CCCK-18 levels, mini–mental status examination and disease duration. CONCLUSION: This study proved that serum nesfatin-1 levels can be used as a biomarker in Alzheimer’s disease by showing a statistically significant high level of serum nesfatin-1 in patients with Alzheimer’s disease. This is the first study to suggest that nesfatin-1 can be used as a biomarker in Alzheimer’s disease. In addition, our study showed that CCCK-18 can be used as a prognostic biomarker for Alzheimer’s disease. Further comprehensive studies should be done to clarify the use of serum nesfatin-1 and CCCK-18 levels as biomarkers for Alzheimer disease (Tab. 3, Fig. 2, Ref. 25). |
||
| Keywords: nesfatin-1, CCCK-18, Alzheimer’s disease, mini-mental status examination | ||
| Published online: 26-Apr-2019 | ||
| Year: 2019, Volume: 120, Issue: 4 | Page From: 295, Page To: 298 | |
| doi:10.4149/BLL_2019_046 |
||
|
|
 download file |
|